Advicenne SA ALDVI

PARIS, September 17, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today reports its 2026 first half financial results, as approved on September 17, 2026, by the Board of Directors. The first half financial report is available on the Company’s website: www.advicenne.com.

PARIS, August 31, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today the voluntary withdrawal of the New Drug Application (NDA) for ADV7103 in the treatment of primary distal Renal Tubular Acidosis (dRTA) in the USA.

PARIS, July 20, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal Renal Tubular Acidosis (dRTA).

PARIS, July 16, 2026--Regulatory News: Advicenne S.A. ("Advicenne" or the "Company") (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today announces its net revenue for the first half of 2026, more than doubled to €2.7 million, the first one reported without the significant negative impact of the early access clawbacks. The reported revenue does not incl

PARIS, July 01, 2026--Regulatory News: Advicenne S.A. (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the unlimited renewal of the Marketing Authorization (MA) for Sibnayal® (a fixed-dose combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the United Kingdom.

PARIS, June 22, 2026--Regulatory News: Advicenne S.A. ("Advicenne" or the "Company") (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that it has secured a two-tranche financing of a nominal amount of up to €3.8 million, through the issuance of bonds subscribed by Cemag Invest and Didier Laurens, Chairman of the Board and CEO of Advicenne,

PARIS, June 01, 2026--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.